Search results
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
Morningstar· 2 days agoHigh obesity drug demand and a scarcity of supply have driven its stock above its intrinsic value.
The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology via Yahoo Finance· 2 days agoMoving forward, Eli Lilly’s R&D efforts are focused on building a pipeline of assets that can reduce muscle loss associated with incretin medications...
The Big Split: 3 Stock Spinoffs Are Coming. Should You Buy?
InvestorPlace· 1 day agoThe result: a bloated stock where neither the primary business nor the side projects do really well....
Novo Nordisk (NVO) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 2 days agoImage source: The Motley Fool. Novo Nordisk (NYSE: NVO) Q1 2024 Earnings Call May 02, 2024, 7:00 a.m. ET Contents: Prepared Remarks Questions and Answers...
Is Eli Lilly Stock A Buy After Weight-Loss Drug Crushes Quarterly Sales Forecasts?
Investor's Business Daily· 4 days agoThose who stayed on Zepbound lost an additional 5.5% of their weight. In another analysis of...
Novo Nordisk announces $6B investment in Ozempic, Wegovy amid shortages
ABC News· 2 days agoAn executive for Novo Nordisk, the maker of popular drugs used for weight loss including Ozempic and...
FTC Warns ‘Junk Patents’ Could Make Drugs Like Ozempic Pricier—Here’s How
Forbes· 5 days agoThe Federal Trade Commission is challenging hundreds of alleged “junk” patent listings filed by...
Earnings call: Novo Nordisk reports a 24% increase in sales By Investing.com
Investing.com· 2 days agoNovo Nordisk (NYSE:NVO) (NOVO-B.CO), a global healthcare company specializing in diabetes and...
Halle Berry's Menopause; Orangutan Treats Wound; Most Influential People in Health
MedPage Today· 2 days agoActress Halle Berry and U.S. Senators unveiled a $275 million bill that aims to boost menopause...
Eli Lilly (LLY) Q1 Earnings Top, Sales Miss, 2024 View Raised
Zacks· 5 days agoEli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises...